Our Pricing

Why Am I Not Losing Weight On Mounjaro 2.5 Mg: What To Expect

Published on: June 03, 2026

If you're experiencing mounjaro 2.5 mg not losing weight, you're not alone—and it's entirely expected. The 2.5 mg starter dose is designed primarily for tolerability and gradual adjustment, not maximum weight loss. At Cured Pharmacy, our UK prescribers help patients understand realistic timelines and dose escalation protocols to achieve sustainable results with Mounjaro, available from £124.99.

Why the 2.5 Mg Dose Is Not Designed for Maximum Weight Loss

Mounjaro 2.5 mg is the initial titration dose, not the therapeutic dose for weight management. The MHRA-approved dosing schedule begins at 2.5 mg to allow your body to adapt to tirzepatide's effects on GIP and GLP-1 receptors, minimising gastrointestinal side effects whilst building tolerance [1].

In the SURMOUNT-1 trial—the pivotal study supporting Mounjaro's weight loss indication—participants didn't remain on 2.5 mg. The protocol escalated doses every four weeks, with meaningful weight loss occurring primarily at maintenance doses of 10 mg and 15 mg [1]. Patients on 2.5 mg typically experience mild appetite reduction and modest metabolic changes, but not the dramatic weight loss seen at higher doses.

Your UK prescriber will have started you on 2.5 mg specifically to reduce the risk of nausea, vomiting, and diarrhoea—the most common side effects when initiating GLP-1 receptor agonists. This conservative approach improves long-term adherence and treatment success.

What Weight Loss Results to Expect on Mounjaro 2.5 Mg

During your first four weeks on Mounjaro 2.5 mg, you may notice subtle changes: reduced cravings, earlier satiety at meals, or stabilised blood glucose if you have type 2 diabetes. However, significant weight reduction is uncommon at this starter dose [1].

Clinical trial data shows that average weight loss on 2.5 mg tirzepatide is approximately 1-3% of total body weight over four weeks—considerably less than the 15-22.5% reductions observed at maintenance doses of 10 mg and 15 mg over 72 weeks [1][2]. For a 90 kg individual, this translates to roughly 0.9-2.7 kg during the initial month, though individual responses vary widely.

Some patients report no weight change on 2.5 mg, which is entirely normal and expected. The starter dose is a stepping stone, not the destination. Your body is adjusting to tirzepatide's dual hormone activity, preparing for more substantial effects as your dose increases under prescriber supervision.

Individual Variation in Early Response

Factors including baseline metabolism, dietary habits, physical activity, sleep quality, and hormonal status all influence initial response to Mounjaro. Patients with higher insulin resistance may experience different early effects compared to those with primarily appetite-driven weight gain. Your UK prescriber will consider these variables when planning your dose escalation schedule.

The Mounjaro Dose Escalation Schedule Explained

The standard UK prescribing protocol for Mounjaro follows a structured escalation: 2.5 mg for four weeks, then 5 mg for four weeks, followed by 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg if clinically appropriate [3]. Each step allows your body to adapt whilst progressively enhancing weight loss effects.

Most patients begin noticing meaningful weight reduction once they reach 5 mg or 7.5 mg, typically 8-12 weeks into treatment. By the time you reach maintenance doses of 10 mg or 15 mg, tirzepatide's full appetite suppression and metabolic benefits become evident [1][2].

Your prescriber may adjust this timeline based on your tolerability and response. Some patients escalate more slowly to manage side effects, whilst others progress steadily through each dose level. The goal is sustainable, long-term weight management—not rapid loss that leads to treatment discontinuation.

When to Contact Your Prescriber

If you experience persistent nausea, vomiting, or other concerning symptoms on 2.5 mg, contact your UK prescriber before escalating. Conversely, if you tolerate the starter dose exceptionally well and are eager to progress, your prescriber can assess whether earlier escalation is appropriate based on your clinical profile and weight loss goals.

Optimising Weight Loss Whilst on the Starter Dose

Although 2.5 mg isn't the therapeutic dose, you can still maximise its effects through lifestyle modifications. Prioritising protein intake (1.6-2.2 g per kg body weight daily) helps preserve lean muscle mass whilst in a caloric deficit, which becomes increasingly important as your dose escalates [4].

Resistance training at least twice weekly supports metabolic health and prevents the muscle loss that can accompany rapid weight reduction. Combining tirzepatide with structured physical activity has been shown to enhance total body composition improvements compared to medication alone [4].

Adequate hydration (2-3 litres daily) and fibre-rich foods can mitigate gastrointestinal side effects whilst supporting satiety. Many patients find that establishing these habits during the 2.5 mg phase makes higher doses more tolerable and effective.

Comparing Mounjaro to Other Weight Loss Treatments Available in the UK

Mounjaro's dual GIP/GLP-1 mechanism distinguishes it from single-pathway treatments like Wegovy (semaglutide) and Saxenda (liraglutide). In head-to-head trials, tirzepatide demonstrated superior weight loss outcomes compared to semaglutide at equivalent treatment durations [2][5].

Wegovy, available at Cured Pharmacy, also uses a dose escalation protocol starting at 0.25 mg weekly. Like Mounjaro's 2.5 mg dose, Wegovy's starter doses are primarily for tolerability rather than maximum efficacy. Both medications require patience during the titration phase.

Orlistat-based treatments work through an entirely different mechanism—blocking dietary fat absorption rather than modulating appetite hormones. These may suit patients who prefer oral medications or have contraindications to injectable GLP-1 therapies. Your UK prescriber can discuss which option aligns best with your medical history and weight loss objectives.

Choosing Between Injectable and Oral Options

Cured Pharmacy now offers Wegovy oral tablets as a pre-order option for patients who prefer pill-based treatment. Whilst injectable tirzepatide and semaglutide currently demonstrate stronger clinical efficacy data, oral formulations provide convenience for those uncomfortable with weekly injections. Discuss your preferences during your free online consultation.

How Cured Pharmacy Supports Your Mounjaro Journey

At Cured Pharmacy, we provide transparent upfront pricing for Mounjaro from £124.99, with no hidden consultation fees. Our UK-registered clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), conducts thorough online assessments to ensure Mounjaro is clinically appropriate for you.

Your prescription is reviewed by a UK prescriber, and genuine MHRA-licensed Mounjaro KwikPens are dispensed from our GPhC-registered pharmacy (9012511). We offer discreet packaging and reliable delivery across the UK, with ongoing support throughout your dose escalation journey.

If you have questions about your progress on 2.5 mg or concerns about side effects, our pharmacy team is available on (+44) 116 4646009. We're committed to helping you achieve sustainable weight loss through evidence-based treatment and personalised clinical care.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen – Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/14269 [accessed 13 August 2026]
4. Lundgren, J. R., Janus, C., Jensen, S. B. K., et al. (2021). Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine, 384(18), 1719–1730. https://doi.org/10.1056/NEJMoa2028198 [accessed 13 August 2026]
5. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence, lifestyle modifications, and individual metabolic response.